Status:
COMPLETED
In Vitro Immunomodulation in Membranous Nephropathy Relapses
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Extramembranous Glomerulopathy
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In order to propose the best therapeutic option to relapsed MN patients with strong activation of the Th17 pathway, the investigators propose to study in vitro the effect of different immunomodulators...
Detailed Description
Membranous Nephropathy (MN) is a rare autoimmune renal disease and the first cause of nephrotic syndrome in adults. In one third of cases, it progresses to end-stage renal failure. Rituximab has shown...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Patient with MN proven on renal biopsy or by the presence of anti-PLA2R1 or anti-THDS71 antibodies
- Relapsed MN, defined as proteinuria \> 3.5g/g after achieving remission (partial or complete, definitions according to KDIGO 2012 guidelines)
- At a distance from any immunosuppressive treatment (at least 6 months)
- Freely given informed consent signed by the patient after clear, fair and appropriate information
- Affiliated to a social security system
Exclusion
- Pregnant or breastfeeding woman
- Patient under 18 years of age
- Persons of legal age
Key Trial Info
Start Date :
May 23 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 6 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05428605
Start Date
May 23 2022
End Date
June 6 2025
Last Update
December 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Universitaire de Nice
Nice, France, 06200